Table 2 Baseline characteristics
Study 1 (SAR) | Study 2 (PAR) | |||
|---|---|---|---|---|
MFNS 100 μg (n=135) | Placebo (n=136) | MFNS 100 μg (n=190) | Placebo (n=191) | |
Age (years) | ||||
Mean (95% CI) | 8.7 (8.5, 9.0) | 8.8 (8.6, 9.1) | 7.6 (7.3, 8.0) | 7.4 (7.1, 7.8) |
Sex (%) | ||||
Male | 84 (62) | 84 (62) | 123 (65) | 109 (57) |
Race (%) | ||||
White | 111 (82) | 113 (83) | 86 (45) | 89 (47) |
Nonwhite | 24 (18) | 23 (17) | 104 (55) | 102 (53) |
Asthma history, | ||||
n (%) | 46 (34) | 62 (46) | 62 (33) | 62 (33) |
Congestion score, LS mean (95% CI)a | 2.20 (2.10, 2.31) | 2.11 (2.00, 2.22) | 2.02 (1.94, 2.10) | 2.07 (1.99, 2.15) |
PAR, n (%) | 95 (70) | 90 (66) | 190 (100) | 191 (100) |
SAR, n (%) | 135 (100) | 136 (100) | 52 (27) | 42 (22) |